213 related articles for article (PubMed ID: 31138602)
21. Targeting AKT1-E17K and the PI3K/AKT Pathway with an Allosteric AKT Inhibitor, ARQ 092.
Yu Y; Savage RE; Eathiraj S; Meade J; Wick MJ; Hall T; Abbadessa G; Schwartz B
PLoS One; 2015; 10(10):e0140479. PubMed ID: 26469692
[TBL] [Abstract][Full Text] [Related]
22. Targeting SPARC expression decreases glioma cellular survival and invasion associated with reduced activities of FAK and ILK kinases.
Shi Q; Bao S; Song L; Wu Q; Bigner DD; Hjelmeland AB; Rich JN
Oncogene; 2007 Jun; 26(28):4084-94. PubMed ID: 17213807
[TBL] [Abstract][Full Text] [Related]
23. Genomically amplified Akt3 activates DNA repair pathway and promotes glioma progression.
Turner KM; Sun Y; Ji P; Granberg KJ; Bernard B; Hu L; Cogdell DE; Zhou X; Yli-Harja O; Nykter M; Shmulevich I; Yung WK; Fuller GN; Zhang W
Proc Natl Acad Sci U S A; 2015 Mar; 112(11):3421-6. PubMed ID: 25737557
[TBL] [Abstract][Full Text] [Related]
24. AKT1 mutations in bladder cancer: identification of a novel oncogenic mutation that can co-operate with E17K.
Askham JM; Platt F; Chambers PA; Snowden H; Taylor CF; Knowles MA
Oncogene; 2010 Jan; 29(1):150-5. PubMed ID: 19802009
[TBL] [Abstract][Full Text] [Related]
25. Distinct roles of AKT isoforms in regulating β1-integrin activity, migration, and invasion in prostate cancer.
Virtakoivu R; Pellinen T; Rantala JK; Perälä M; Ivaska J
Mol Biol Cell; 2012 Sep; 23(17):3357-69. PubMed ID: 22809628
[TBL] [Abstract][Full Text] [Related]
26. AKT1 E17K in Colorectal Carcinoma Is Associated with BRAF V600E but Not MSI-H Status: A Clinicopathologic Comparison to PIK3CA Helical and Kinase Domain Mutants.
Hechtman JF; Sadowska J; Huse JT; Borsu L; Yaeger R; Shia J; Vakiani E; Ladanyi M; Arcila ME
Mol Cancer Res; 2015 Jun; 13(6):1003-8. PubMed ID: 25714871
[TBL] [Abstract][Full Text] [Related]
27. Polyethylenimine-complexed plasmid particles targeting focal adhesion kinase function as melanoma tumor therapeutics.
Li S; Dong W; Zong Y; Yin W; Jin G; Hu Q; Huang X; Jiang W; Hua ZC
Mol Ther; 2007 Mar; 15(3):515-23. PubMed ID: 17285141
[TBL] [Abstract][Full Text] [Related]
28. PHLPP1 mediates melanoma metastasis suppression through repressing AKT2 activation.
Yu Y; Dai M; Lu A; Yu E; Merlino G
Oncogene; 2018 Apr; 37(17):2225-2236. PubMed ID: 29391600
[TBL] [Abstract][Full Text] [Related]
29. Deltex-3-like (DTX3L) stimulates metastasis of melanoma through FAK/PI3K/AKT but not MEK/ERK pathway.
Thang ND; Yajima I; Kumasaka MY; Iida M; Suzuki T; Kato M
Oncotarget; 2015 Jun; 6(16):14290-9. PubMed ID: 26033450
[TBL] [Abstract][Full Text] [Related]
30. AKT1 (E17K) mutation profiling in breast cancer: prevalence, concurrent oncogenic alterations, and blood-based detection.
Rudolph M; Anzeneder T; Schulz A; Beckmann G; Byrne AT; Jeffers M; Pena C; Politz O; Köchert K; Vonk R; Reischl J
BMC Cancer; 2016 Aug; 16():622. PubMed ID: 27515171
[TBL] [Abstract][Full Text] [Related]
31. Functional and therapeutic significance of Akt deregulation in malignant melanoma.
Robertson GP
Cancer Metastasis Rev; 2005 Jun; 24(2):273-85. PubMed ID: 15986137
[TBL] [Abstract][Full Text] [Related]
32. Whole-genome CRISPR screening identifies PI3K/AKT as a downstream component of the oncogenic GNAQ-focal adhesion kinase signaling circuitry.
Arang N; Lubrano S; Rigiracciolo DC; Nachmanson D; Lippman SM; Mali P; Harismendy O; Gutkind JS
J Biol Chem; 2023 Feb; 299(2):102866. PubMed ID: 36596361
[TBL] [Abstract][Full Text] [Related]
33. A gain of function mutation in AKT1 increases hexokinase 2 and diminishes oxidative stress in meningioma.
Singh S; Lathoria K; Umdor SB; Singh J; Suri V; Sen E
Cytokine; 2024 Apr; 176():156535. PubMed ID: 38325141
[TBL] [Abstract][Full Text] [Related]
34. In vivo cleaved CDCP1 promotes early tumor dissemination via complexing with activated β1 integrin and induction of FAK/PI3K/Akt motility signaling.
Casar B; Rimann I; Kato H; Shattil SJ; Quigley JP; Deryugina EI
Oncogene; 2014 Jan; 33(2):255-68. PubMed ID: 23208492
[TBL] [Abstract][Full Text] [Related]
35. Sphingosine kinase 1 promotes tumor progression and confers malignancy phenotypes of colon cancer by regulating the focal adhesion kinase pathway and adhesion molecules.
Liu SQ; Su YJ; Qin MB; Mao YB; Huang JA; Tang GD
Int J Oncol; 2013 Feb; 42(2):617-26. PubMed ID: 23232649
[TBL] [Abstract][Full Text] [Related]
36. miR-300 regulates the epithelial-mesenchymal transition and invasion of hepatocellular carcinoma by targeting the FAK/PI3K/AKT signaling pathway.
Wang R; Yu Z; Chen F; Xu H; Shen S; Chen W; Chen L; Su Q; Zhang L; Bi J; Zeng W; Li W; Huang X; Wang Q
Biomed Pharmacother; 2018 Jul; 103():1632-1642. PubMed ID: 29864952
[TBL] [Abstract][Full Text] [Related]
37. Mutant AKT1-E17K is oncogenic in lung epithelial cells.
De Marco C; Malanga D; Rinaldo N; De Vita F; Scrima M; Lovisa S; Fabris L; Carriero MV; Franco R; Rizzuto A; Baldassarre G; Viglietto G
Oncotarget; 2015 Nov; 6(37):39634-50. PubMed ID: 26053093
[TBL] [Abstract][Full Text] [Related]
38. FAK activates AKT-mTOR signaling to promote the growth and progression of MMTV-Wnt1-driven basal-like mammary tumors.
Paul R; Luo M; Mo X; Lu J; Yeo SK; Guan JL
Breast Cancer Res; 2020 Jun; 22(1):59. PubMed ID: 32493400
[TBL] [Abstract][Full Text] [Related]
39. A computational approach for investigating the mutational landscape of RAC-alpha serine/threonine-protein kinase (AKT1) and screening inhibitors against the oncogenic E17K mutation causing breast cancer.
Thirumal Kumar D; Jain N; Evangeline J; Kamaraj B; Siva R; Zayed H; George Priya Doss C
Comput Biol Med; 2019 Dec; 115():103513. PubMed ID: 31698236
[TBL] [Abstract][Full Text] [Related]
40. Specific gene expression signatures induced by the multiple oncogenic alterations that occur within the PTEN/PI3K/AKT pathway in lung cancer.
De Marco C; Laudanna C; Rinaldo N; Oliveira DM; Ravo M; Weisz A; Ceccarelli M; Caira E; Rizzuto A; Zoppoli P; Malanga D; Viglietto G
PLoS One; 2017; 12(6):e0178865. PubMed ID: 28662101
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
